Improving the Therapeutic Efficiency of Hypoxic-Activated Prodrugs by Enhancing Hypoxia in Solid Tumors
- 29 March 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 8 (4) , 1604-1612
Abstract
The low sensitivity of hypoxic regions in solid tumors to radiotherapy and chemotherapy remains a major obstacle to cancer treatment. By taking advantage of hypoxic-activated prodrugs, tirapazamine (TPZ), generating cytotoxic reductive products and the glucose oxidase (GOx)-based glucose oxidation reaction, we designed a nanodrug-loading system that combined TPZ-induced chemotherapy with GOx-mediated cancer-orchestrated starvation therapy and cancer oxidation therapy. In this work, we first prepared mesoporous silica (MSN) loaded with TPZ. Then, in order to prevent the leakage of TPZ in advance, the surface was coated with a layer of carMOF formed by Fe3+ and carbenicillin (car), and GOx was adsorbed on the outermost layer to form the final nanosystem MSN-TPZ@carMOF-GOx (MT@c-G). GOx could effectively consume oxygen and catalyzed glucose into gluconic acid and hydrogen peroxide. First, the generated gluconic acid lowered the pH of tumor tissues, promoted the decomposition of carMOF, and released TPZ. Second, oxygen consumption could improve the degree of hypoxia in tumor tissues, so that enhanced the activity of TPZ. Furthermore, GOx could generate cancer-orchestrated starvation/oxidation therapy. Therefore, our study provided a new strategy that TPZ combined with GOx achieved starvation/oxidation/chemotherapy for enhancing anticancer effects in hypoxic regions.Keywords
Funding Information
- Natural Science Foundation of Hebei Province (B2020201091, B2021201038)
- Talent Training Program of Hebei University (521000981169, 521000981196)
- Hebei Youth Top Talent Project
This publication has 23 references indexed in Scilit:
- Tumor-Penetrating Nanoparticles for Enhanced Anticancer Activity of Combined Photodynamic and Hypoxia-Activated TherapyACS Nano, 2017
- The hypoxic tumor microenvironment: A driving force for breast cancer progressionBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2016
- Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxiaChinese Journal of Cancer, 2014
- Efficient Hypoxic Activation of the Anticancer Agent AQ4N by CYP2S1 and CYP2W1Molecular Pharmacology, 2010
- Hypoxic Tumor Microenvironment and Cancer Cell DifferentiationCurrent Molecular Medicine, 2009
- The tumor microenvironment and metastatic diseaseClinical & Experimental Metastasis, 2008
- Chronic Hypoxia Decreases Synthesis of Homologous Recombination Proteins to Offset Chemoresistance and RadioresistanceCancer Research, 2008
- Hypoxia — a key regulatory factor in tumour growthNature Reviews Cancer, 2002
- Predictive Power of the Tumor Oxygenation Status1999
- Potential bioreductive alkylating agents. 1. Benzoquinone derivativesJournal of Medicinal Chemistry, 1972